Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135774 | 0.90 | ALDH1A1 (0.68) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135773 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135884 | 0.81 | ALDH1A1 (0.57) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135978 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135770 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135852 | 0.79 | ALDH1A1 (0.54) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16136123 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135998 | 0.76 | ALDH1A1 (0.45) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135889 | 0.76 | ALDH1A1 (0.44) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16111159 | 0.76 | ALDH1A1 (0.47) | ALDH1A1HTTLMNAGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014160478-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | ALDH1A1 514/4885HTT 4260/4885LMNA 1994/4885 |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | ALDH1A1 514/4885HTT 4260/4885LMNA 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.